Sectors

SBFM
Sunshine Biopharma, Inc.
1.19
1 x 1.15
1 x 1.32
bid
ask
-
0.03
2.87%
09:36 AM
timesize
Ytd-90.37%
1y-91.54%
1.18
day range
1.21
1.10
52 week range
24.30
Open1.21Prev Close1.22Low1.18High1.21Mkt Cap2.81M
Vol36.88KAvg Vol1.89MEPS-6.08P/E-0.19Forward P/E0.02
Beta1.16Short Ratio0.39Inst. Own1.84%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1850-d Avg1.94200-d Avg9.571yr Est300.00
Earning
DateForEstimateReportedSurprisesurprise %
2024-11-052024-090-0.94N/AN/A
2024-08-162024-060-9.94N/AN/A
2024-05-202024-030-40N/AN/A
2024-03-282023-120-100N/AN/A
2023-11-132023-090-80N/AN/A
2023-08-112023-060-40N/AN/A
Upgrade / Downgrade
DateFirmActionFromTo
2024-12-05Aegis CapitalUpgradeBuyBuy
2023-08-07Aegis CapitalUpgradeBuy
Profile
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is based in Fort Lauderdale, Florida.
Insider Holder
DateNameRelationQuantityDescription
2021-01-05MERZOUKI ABDERRAZZAKChief Operating Officer23.34MStock Award(Grant)
2022-11-29SEBAALY CAMILLEChief Financial Officer174.47KPurchase
2021-01-05SLILATY STEVE NChief Executive Officer23.34MStock Award(Grant)
Institution Ownership
Report DateOrganizationPositionValuePercentage
2024-09-29Bank of America Corporation34.48K103.44K1.72%
2024-09-29Nordwand Advisors, LLC 500.001.50K0.03%
2024-09-29Rise Advisors, LLC 1.003.000.00%
2024-09-29Farther Finance Advisors, Llc1.003.000.00%
2024-09-29National Bank of Canada/FI7.0021.000.00%
2024-09-29Federation Des Caisses Desjardins Du Quebec1.003.000.00%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2024-08-30Fidelity NASDAQ Composite Index Fund11.0033.000.00%
Split
SplitDate
1 : 102026-06-01
1 : 202024-08-08
1 : 1002024-04-17
1 : 2002022-02-09
1 : 202020-04-06
1 : 202019-02-01